RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $25.67 Average PT from Analysts

RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) has earned a consensus rating of "Moderate Buy" from the twelve research firms that are covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $25.67.

Several research firms have commented on RAPT. SVB Leerink cut RAPT Therapeutics from an "outperform" rating to a "market perform" rating and lowered their price target for the company from $42.00 to $10.00 in a report on Wednesday, February 21st. Wolfe Research began coverage on RAPT Therapeutics in a report on Thursday, February 15th. They issued an "outperform" rating and a $39.00 price target for the company. Leerink Partnrs cut RAPT Therapeutics from an "outperform" rating to a "market perform" rating in a report on Wednesday, February 21st. HC Wainwright cut RAPT Therapeutics from a "buy" rating to a "neutral" rating in a report on Wednesday, February 21st. Finally, Barclays reduced their price objective on RAPT Therapeutics from $35.00 to $13.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 21st.

RAPT Therapeutics Trading Down 4.2 %

RAPT Therapeutics stock traded down $0.35 during midday trading on Thursday, reaching $8.01. 449,877 shares of the company were exchanged, compared to its average volume of 1,218,823. The firm's 50-day simple moving average is $14.70 and its 200-day simple moving average is $16.49. RAPT Therapeutics has a 1 year low of $6.86 and a 1 year high of $27.35.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last posted its quarterly earnings data on Thursday, March 7th. The company reported ($0.80) EPS for the quarter, topping analysts' consensus estimates of ($0.85) by $0.05. Equities research analysts predict that RAPT Therapeutics will post -3.19 earnings per share for the current fiscal year.

Institutional Investors Weigh In On RAPT Therapeutics

A number of institutional investors have recently made changes to their positions in RAPT. Braidwell LP bought a new stake in shares of RAPT Therapeutics in the 2nd quarter valued at approximately $18,408,000. State Street Corp grew its stake in RAPT Therapeutics by 159.5% during the 3rd quarter. State Street Corp now owns 1,273,891 shares of the company's stock worth $30,650,000 after buying an additional 783,026 shares during the last quarter. TimesSquare Capital Management LLC bought a new position in RAPT Therapeutics during the 4th quarter worth $12,533,000. Perceptive Advisors LLC grew its stake in RAPT Therapeutics by 27.4% during the 1st quarter. Perceptive Advisors LLC now owns 2,291,608 shares of the company's stock worth $42,051,000 after buying an additional 492,653 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in RAPT Therapeutics by 9.1% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 4,334,683 shares of the company's stock worth $79,108,000 after buying an additional 359,978 shares during the last quarter. 99.09% of the stock is currently owned by institutional investors.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.